Cogitars GmbH was founded in 2013. The main focus of the company is on statistical support for Biotech- and Pharma Companies including Bayesian trials in phase 1, ranging from technical implementation to protocol writing and negotation with regulators. Cogitars has specific expertise in the field and, where required, works with a network of international experts to provide best solutions to its customers.
Oliver Schönborn-Kellenberger received his MSc in Mathematics at Georg August University in Göttingen. In 2004 he started as statistician at a CRO [PRA] before joining Novartis Pharma AG in 2006. In 2008, he moved to Novartis Oncology where he took over responsibility for a large compound in early development. He pursued an opportunity at Imclone International in 2012. Oliver Schönborn-Kellenberger has specific expertise in management of transition activities (Proof of Concept/Phase II to Phase III). During his career, he was involved in various fully Bayesian single agent and combination escalation trials as well as in Bayesian Phase II trials. His project experience includes Hsp90, pan-RAF, Notch inhibitors and bispecific antibody and amongst others, he worked in indications such as NSCLC, gastric tumors and hodgkin lymphoma.
Michael Kruse holds a degree as economist (Diplom Volkswirt) and studied in Hamburg and Liverpool. He joined Cogitars GmbH in 2015. Michael is specialised in building up professional business structures which will be helpful in Cogitars' growth process over the next years. Since Michael worked in Berlin as a consultant for companies in the health sector, he has a deep understanding of both pharmaceutical as well as medtec companies and their business models. Michael is MP in his hometown, the city of Hamburg.
Offering better treatments to the right patients through improved drug development motivates us every day to go the extra mile. Our own practical experience clearly showed us that Bayesian adaptive trials offer a substantial advantage in early drug development. Furthermore, we are convinced that Bayesian methods and evidence synthesis can help companies to make better use of their data to improve the developemnt of their compounds.
Our business is guided by our three corporate values which reflect the way we work with our customers.